Expression of truncated HER2 and its prognostic value in HER2-positive breast cancer patients
Purpose: The purpose of this work was to assess the truncated form of human epidermal growth factor receptor 2 (HER2) such as p95-HER2 expression in HER2-positive breast cancer (BC) patients who developed metastatic disease after adjuvant treatment with a trastuzumab-containing regimen. Patients and...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2018-06-01
|
| Series: | Journal of the Egyptian National Cancer Institute |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1110036218300268 |
| _version_ | 1818984420064886784 |
|---|---|
| author | Alaa Mohamed Maria Mohamed El-Shebiney Ayman Mohamed El-Saka Yomna Zamzam |
| author_facet | Alaa Mohamed Maria Mohamed El-Shebiney Ayman Mohamed El-Saka Yomna Zamzam |
| author_sort | Alaa Mohamed Maria |
| collection | DOAJ |
| description | Purpose: The purpose of this work was to assess the truncated form of human epidermal growth factor receptor 2 (HER2) such as p95-HER2 expression in HER2-positive breast cancer (BC) patients who developed metastatic disease after adjuvant treatment with a trastuzumab-containing regimen. Patients and methods: Thirty-two histologically diagnosed HER2-positive BC patients who developed distant failure after treatment with trastuzumab-based chemotherapy (CT) regimen as an adjuvant therapy were included in the study. Immunohistochemistry (IHC) method was used to analyze p95-HER2 expression in the formalin-fixed, paraffin-embedded (FFPE) blocks of the enrolled patients. Results: p95-HER2 was positive in 34.4% of the patients. The median overall survival (OS) was 22.5 and 35 months for p95-HER2 positive and negative patients, respectively (p = 0.036) and the median time to metastases was 14 and 21 months, respectively (p = 0.006). There was a statistically significant association between positive p95-HER2 expression and negative hormonal receptors expression (p = 0.004), high Ki-67 expression (p < 0.001) and development of visceral metastasis (p = 0.034). Conclusion: Expression of p95-HER2 in HER2-positive BC patients is significantly associated with negative hormonal receptors expression, high Ki-67 expression, presence of visceral metastases and worse overall survival. A larger study is required to confirm its association with different prognostic factors and its effect on survival. Keywords: Breast cancer, HER2-positive, Trastuzumab, p95-HER2 |
| first_indexed | 2024-12-20T18:18:43Z |
| format | Article |
| id | doaj.art-5c830a0c09e342f6b7425f7f0ad412f9 |
| institution | Directory Open Access Journal |
| issn | 1110-0362 |
| language | English |
| last_indexed | 2024-12-20T18:18:43Z |
| publishDate | 2018-06-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | Journal of the Egyptian National Cancer Institute |
| spelling | doaj.art-5c830a0c09e342f6b7425f7f0ad412f92022-12-21T19:30:19ZengSpringerOpenJournal of the Egyptian National Cancer Institute1110-03622018-06-013024955Expression of truncated HER2 and its prognostic value in HER2-positive breast cancer patientsAlaa Mohamed Maria0Mohamed El-Shebiney1Ayman Mohamed El-Saka2Yomna Zamzam3Clinical Oncology Department, Faculty of Medicine, Tanta University, Egypt; Corresponding author.Clinical Oncology Department, Faculty of Medicine, Tanta University, EgyptPathology Department, Faculty of Medicine, Tanta University, EgyptPathology Department, Faculty of Medicine, Tanta University, EgyptPurpose: The purpose of this work was to assess the truncated form of human epidermal growth factor receptor 2 (HER2) such as p95-HER2 expression in HER2-positive breast cancer (BC) patients who developed metastatic disease after adjuvant treatment with a trastuzumab-containing regimen. Patients and methods: Thirty-two histologically diagnosed HER2-positive BC patients who developed distant failure after treatment with trastuzumab-based chemotherapy (CT) regimen as an adjuvant therapy were included in the study. Immunohistochemistry (IHC) method was used to analyze p95-HER2 expression in the formalin-fixed, paraffin-embedded (FFPE) blocks of the enrolled patients. Results: p95-HER2 was positive in 34.4% of the patients. The median overall survival (OS) was 22.5 and 35 months for p95-HER2 positive and negative patients, respectively (p = 0.036) and the median time to metastases was 14 and 21 months, respectively (p = 0.006). There was a statistically significant association between positive p95-HER2 expression and negative hormonal receptors expression (p = 0.004), high Ki-67 expression (p < 0.001) and development of visceral metastasis (p = 0.034). Conclusion: Expression of p95-HER2 in HER2-positive BC patients is significantly associated with negative hormonal receptors expression, high Ki-67 expression, presence of visceral metastases and worse overall survival. A larger study is required to confirm its association with different prognostic factors and its effect on survival. Keywords: Breast cancer, HER2-positive, Trastuzumab, p95-HER2http://www.sciencedirect.com/science/article/pii/S1110036218300268 |
| spellingShingle | Alaa Mohamed Maria Mohamed El-Shebiney Ayman Mohamed El-Saka Yomna Zamzam Expression of truncated HER2 and its prognostic value in HER2-positive breast cancer patients Journal of the Egyptian National Cancer Institute |
| title | Expression of truncated HER2 and its prognostic value in HER2-positive breast cancer patients |
| title_full | Expression of truncated HER2 and its prognostic value in HER2-positive breast cancer patients |
| title_fullStr | Expression of truncated HER2 and its prognostic value in HER2-positive breast cancer patients |
| title_full_unstemmed | Expression of truncated HER2 and its prognostic value in HER2-positive breast cancer patients |
| title_short | Expression of truncated HER2 and its prognostic value in HER2-positive breast cancer patients |
| title_sort | expression of truncated her2 and its prognostic value in her2 positive breast cancer patients |
| url | http://www.sciencedirect.com/science/article/pii/S1110036218300268 |
| work_keys_str_mv | AT alaamohamedmaria expressionoftruncatedher2anditsprognosticvalueinher2positivebreastcancerpatients AT mohamedelshebiney expressionoftruncatedher2anditsprognosticvalueinher2positivebreastcancerpatients AT aymanmohamedelsaka expressionoftruncatedher2anditsprognosticvalueinher2positivebreastcancerpatients AT yomnazamzam expressionoftruncatedher2anditsprognosticvalueinher2positivebreastcancerpatients |